Genetics can provide a systematic approach to discovering the tissues and cell types relevant for a complex disease or trait. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
45/100
Ninety per cent of the human population has been right-handed since the Paleolithic, yet the brain signature and genetic basis of handedness remain poorly characterized. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
45/100
As more biomarkers for Alzheimer's disease and age-related brain conditions become available, more sophisticated analytic approaches are needed to take full advantage of the information they convey. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recently, deep-learning-based approaches have been proposed for the classification of neuroimaging data related to Alzheimer's disease (AD), and significant progress has been made. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Anti-amyloid monoclonal antibodies have finally achieved their translational breakthrough after many years of unmet expectations. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
45/100
Patients on donepezil showed selective and significant (p<0.05) improvement on the memory subscale of the Dementia Rating Scale. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Patients completed a survey assessing statin-associated, cognitive-specific adverse drug reaction (ADR) characteristics, relation of the ADR to specific statin and dose (or potency), and time course of symptom onset and recovery. 5 key findings →
Participants: 128 Evidence: low
Full summary, score breakdown and related studies → Original source
Behavioural troubles due to frontotemporal dementia (FTD) are difficult to treat. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Curcumin possesses many properties which may prevent or ameliorate pathological processes underlying age-related cognitive decline, dementia or mood disorders. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
After a mean follow-up of 3.9 years, 131 persons developed Alzheimer disease. 5 key findings →
Participants: 131 Evidence: low
Full summary, score breakdown and related studies → Original source
Groups of spouse (N = 285) and adult child (N = 244) caregivers of elderly parents suffering from Alzheimer's disease were interviewed regarding their caregiving behaviors, evaluations of caregiving, and general psychological well-being. 1 key finding →
Participants: 285 Evidence: low
Full summary, score breakdown and related studies → Original source
More than 3500 Cochrane Reviews are now available in full, including information on the methods, eligible studies, analyses, results, and conclusions. 2 key findings →
Participants: 8,000 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a pervasive neurodegenerative disorder, and new approaches for its prevention and therapy are critically needed. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Caregiving dynamics were studied in a sample of 157 Black caregivers of elders suffering from Alzheimer's disease and other dementias. 2 key findings →
Participants: 472 Evidence: low
Full summary, score breakdown and related studies → Original source
Internal consistency, item reliability, and between-rater reliability were high. 5 key findings →
Participants: 115 Evidence: low
Full summary, score breakdown and related studies → Original source
45/100
Our results show that DICE-net achieved an accuracy of 83.28% in the AD-CN problem using Leave-One-Subject-Out validation, outperforming several baseline models, and achieving good generalization performance. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
45/100
Outcome was better for patients who had an LPV shunt than for those with an MPV shunt, although most differences were not statistically significant. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
45/100
Alzheimer's Disease (AD) is the most common cause of dementia globally. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our data indicated that the levels of triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein A-I (ApoA-I), ApoB, ApoE, lipoprotein (a) (Lp(a)) of mutant genotypes in ApoE c.61G > A and c.761T > A genetic variants were different from those subjects with wild genotype in HD patients and healthy controls. 2 key findings →
Participants: 288 Evidence: low
Full summary, score breakdown and related studies → Original source
Apolipoprotein E type 4 allele (ApoE∊4) is known as a risk gene for the late-onset Alzheimer’s disease, and the relationship between ApoE∊4 and cognitive function of the elderly people has drawn the attention of the scientists. 1 key finding →
Participants: 156 Evidence: low
Full summary, score breakdown and related studies → Original source
Children with Down syndrome (DS) experience congenital and functional medical issues that predispose them to obstructive sleep apnea (OSA). 4 key findings →
Participants: 177 Evidence: low
Full summary, score breakdown and related studies → Original source
Major categories of reasons for use of antipsychotic medications in the 204 NH residents in the study sample were behavioral (n = 171), psychiatric (n = 159), emotional states (n = 105), and cognitive diagnoses or symptoms (n = 114). 5 key findings →
Participants: 171 Evidence: low
Full summary, score breakdown and related studies → Original source
There is little information on the dynamics of BDNF in the CSF in the continuum between healthy aging, MCI and AD. 2 key findings →
Participants: 128 Evidence: low
Full summary, score breakdown and related studies → Original source
CSF YKL-40 and chitotriosidase levels are increased in individuals with clinical FTD syndromes, particularly due to AD pathology. 4 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
45/100
Rapamycin is not detectable in the CSF before or after treatment, but several Alzheimer's disease and inflammatory biomarkers increase after treatment. 4 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →